Renal Anemia – Landscape & Forecast – Disease Landscape & Forecast (G7)

Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of chronic hypoxia, cardiovascular disease, and mortality. The current management of renal anemia involves oral and IV iron formulations, ESAs, and HIF-PH inhibitors. Although treatments are available, substantial opportunity remains for safe oral drugs that are less frequently dosed and more effective in reaching target Hb levels. The renal anemia therapy market will expand over the 2023-2033 forecast period, fueled by the uptake of HIF-PH inhibitors and increasing diagnosis and treatment rates over the forecast period. Physicians are optimistic about the HIF-PH inhibitors because they believe this class offers several benefits over conventional ESAs, such as oral administration, lower cost, physiological levels of endogenous EPO production, and improved iron utilization efficiency.

Questions answered

• What is the prevalence of renal anemia in the major pharmaceutical markets under study?
• How is renal anemia currently treated? Will ESAs maintain their strong market position, and how much pressure will they face from new entrants?
• What is the commercial potential of novel HIF-PH inhibitors? How do nephrologists rate these drug candidates?
• Will establishing cardiovascular (CV) safety be key for the market uptake of HIF-PH inhibitors, in view of the CV issues associated with current therapies?
• How will the renal anemia market evolve over the next 10 years?

Content highlights

• Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan
• Primary research: 19 country-specific interviews with thought-leading nephrologists; supported by survey data collected for this and other Clarivate research
• Epidemiology: Prevalence of renal anemia by country and diagnosed / drug-treated rates
• Drug treatments: Coverage of key current and emerging therapies
• Market forecast features: 10-year, annualized, drug-level sales and patient share of key renal anemia therapies through 2033, segmented by brands / generics

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.